Application of SELDI-TOF-MS Coupled With an Artificial Neural Network Model to the Diagnosis of Pancreatic Cancer

Background: There are no satisfactory biomarkers for screening pancreatic cancer. The surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technique has been used to identify biomarkers for different types of cancers. A new and reliable SELDI proteomic method for diagnosing pancreatic cancer is needed. Methods: Four hundred and fifty-five serum samples were tested by SELDI-TOF-MS matching on a gold chip. Samples were assigned to 1 of 2 subsets according to collection order, viz., a training set, and a testing set. The training set was used to identify statistically significant peaks and to develop the artificial neural network (ANN) model for diagnosing pancreatic cancer. The testing set was used in a blind test to validate the diagnostic efficiency of the ANN model. Results: A total of 62 proteins that differed between patients and controls were identified ( P <0.05). Nine of these proteins ( P <0.01; m/z at 4218 Da, 4238 Da, 4264 Da, 4480 Da, 5805 Da, 5928 Da, 9033 Da, 9258 Da, and 9299 Da) were chosen to develop the ANN. The model was subjected to a blind test using the testing set for diagnosis of pancreatic cancer. Sensitivity and specificity were 66.67% and 95.98%, respectively, and the accuracy was 93.47%. Conclusion: These preliminary results suggest that patients with pancreatic cancer may have serum proteins that differ from healthy controls. The ANN is a new method for diagnosing and identifying pancreatic cancer. * SELDI-TOF-MS : surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ANN : artificial neural network ERCP : endoscopic retrograde cholangiopancreatography CA19-9 : carbohydrate antigen 19-9 SPA : sinapinic acid CV : coefficient of variance ROC : receiver-operating characteristic PPV : positive predictive value NPV : negative predictive value MALDI-MS : matrix-assisted laser desorption/ionization mass spectrometry

[1]  Xiaodong Zhu,et al.  New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology. , 2004, World journal of gastroenterology.

[2]  A. Partin,et al.  SELDI protein profiling of dunning R‐3327 derived cell lines: Identification of molecular markers of prostate cancer progression , 2007, The Prostate.

[3]  R. Banks.  Preanalytical influences in clinical proteomic studies: raising awareness of fundamental issues in sample banking. , 2008, Clinical chemistry.

[4]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[5]  O John Semmes,et al.  Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Ian Eardley,et al.  Urinary biomarker profiling in transitional cell carcinoma , 2006, International journal of cancer.

[7]  W. Greenhalf,et al.  Hereditary pancreatitis and secondary screening for early pancreatic cancer. , 2005, Roczniki Akademii Medycznej w Bialymstoku.

[8]  Ming Xu,et al.  Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. , 2005, European urology.

[9]  Yun Lu,et al.  Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. , 2008, World journal of gastroenterology.

[10]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[11]  J. K. Lee,et al.  Clinical usefulness of carbohydrate antigen 19‐9 as a screening test for pancreatic cancer in an asymptomatic population , 2004, Journal of gastroenterology and hepatology.

[12]  H. Lai,et al.  Plasma proteomic pattern as biomarkers for ovarian cancer. , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[13]  A. Vlahou,et al.  Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. , 2005, Oncology reports.

[14]  Paulo J. G. Lisboa,et al.  A review of evidence of health benefit from artificial neural networks in medical intervention , 2002, Neural Networks.

[15]  D. Chan,et al.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. , 2008, Clinical chemistry.

[16]  H. El‐Serag,et al.  The epidemiology of pancreatic cancer in the United States: changes below the surface , 2006, Alimentary pharmacology & therapeutics.

[17]  Jos H Beijnen,et al.  Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. , 2006, World journal of gastroenterology.

[18]  Alain Van Dorsselaer,et al.  Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. , 2006, Journal of proteome research.

[19]  D. Chan,et al.  Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.

[20]  E. Izbicka,et al.  Fine-needle aspiration in PreservCyt®: a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF , 2004, Modern Pathology.

[21]  Graham Ball,et al.  New approaches to identification of bacterial pathogens by surface enhanced laser desorption/ionization time of flight mass spectrometry in concert with artificial neural networks, with special reference to Neisseria gonorrhoeae. , 2005, Journal of medical microbiology.

[22]  Wei Zhang,et al.  Application of serum SELDI proteomic patterns in diagnosis of lung cancer , 2005, BMC Cancer.